BCAL Diagnostics Limited
BCAL Diagnostics Limited
Your view on BDX.AX
Overview
What the company does, where it operates, and who runs it.
About BCAL Diagnostics Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Anne-Louise Arnett
- Headquarters
- 50 Clarence Street, Sydney, NSW, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Anne-Louise Arnett
- Headquarters
- 50 Clarence Street, Sydney, NSW, AU
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring.
This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for BCAL Diagnostics Limited. Starting points for BCAL Diagnostics Limited: EPS -AUD 0.02, beta 0.82 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for BCAL Diagnostics Limited. BCAL Diagnostics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for BCAL Diagnostics Limited. Trailing twelve-month EPS for BCAL Diagnostics Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for BCAL Diagnostics Limited. BCAL Diagnostics Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| AT1.AXAtomo Diagnostics Limited | Healthcare | Medical - Devices | — | ||
| EMD.AXEmyria Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| EYE.AXNova Eye Medical Limited | Healthcare | Medical - Devices | — | ||
| HMD.AXHeraMED Limited | Healthcare | Medical - Devices | — | ||
| IDT.AXIDT Australia Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| IIQ.AXINOVIQ Ltd | Healthcare | Medical - Diagnostics & Research | — | ||
| MAP.AXMicroba Life Sciences Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ILMNIllumina, Inc. | Healthcare | NASDAQ | $31.8B | ||
| IMDXInsight Molecular Diagnostics Inc. | Healthcare | NASDAQ | $52.1M | ||
| IME.AXImExHS Limited | Healthcare | ASX | — | ||
| IMMVFImmunovia AB (publ) | Healthcare | OTC | $6.1M | ||
| IQVIQVIA Holdings Inc. | Healthcare | NYSE | $42.5B | ||
| ISPCiSpecimen Inc. | Healthcare | NASDAQ | $1.3M | ||
| IVROInVitro International | Healthcare | OTC | $1.8M | ||
| IZO.CNIzotropic Corporation | Healthcare | CNQ | $20.6M | ||
| IZOZFIzotropic Corporation | Healthcare | OTC | $11.9M | ||
| JMPHFLeveljump Healthcare Corp. | Healthcare | OTC | $15.2M | ||
| LDDDLongduoduo Company Limited | Healthcare | OTC | $15.3M | ||
| LHLabcorp Holdings Inc. | Healthcare | NYSE | $30.1B | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of BCAL Diagnostics Limited.